Abstract:Twenty‐seven novel l‐tryptophan derivatives with strong antioxidant potential were designed and synthesized according to the reported l‐tryptophan derivatives with submicromolar butyrylcholinesterase inhibitory activity. Compounds 3a‐18 and 3b‐1 with the strongest inhibitory activity, also exhibited extraordinary antioxidant activity, inhibitory activity against β‐amyloid1–42 self‐aggregation, and low cell toxicity. Alzheimer's disease (AD) is a multifactorial neurological disease, and the multitarget directed ligand (MTDL) strategy may be an effective approach to delay its progression. Based on this strategy, 27 derivatives of l‐tryptophan, 3a‐1–3d‐1, were designed, synthesized, and evaluated for their biological activity. Among them, IC50 (inhibitor concentration resulting in 50% inhibitory activity) values of compounds 3a‐18 and 3b‐1 were 0.58 and 0.44 μM for human serum butyrylcholinesterase (hBuChE), respectively, and both of them exhibited more than 30‐fold selectivity for human serum acetylcholinesterase. Enzyme kinetics studies showed that these two compounds were mixed inhibitors of hBuChE. In addition, these two derivatives possessed extraordinary antioxidant activity in OH radical scavenging and oxygen radical absorption capacity fluorescein assays. Meanwhile, these compounds could also prevent β‐amyloid (Aβ) self‐aggregation and possessed low toxicity on PC12 and AML12 cells. Molecular modeling studies revealed that these two compounds could interact with the choline binding site, acetyl binding site, and peripheral anionic site to exert submicromolar BuChE inhibitory activity. In the vitro blood–brain barrier permeation assay, compounds 3a‐18 and 3b‐1 showed enough blood–brain barrier permeability. In drug‐likeness prediction, compounds 3a‐18 and 3b‐1 showed good gastrointestinal absorption and a low risk of human ether‐a‐go‐go‐related gene toxicity. Therefore, compounds 3a‐18 and 3b‐1 are potential multitarget anti‐AD lead compounds, which could work as powerful antioxidants with submicromolar selective inhibitory activity for hBuChE as well as prevent Aβ self‐aggregation.

Design, Synthesis, and Biological Evaluation of 4‐aminopyrimidine or 4,6‐diaminopyrimidine Derivatives As Beta Amyloid Cleaving Enzyme‐1 Inhibitors

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

Design, Synthesis, and Biological Evaluation of 2-Arylethenylquinoline Derivatives As Multifunctional Agents for the Treatment of Alzheimer's Disease.

Identification of N-phenyl-3-methoxy-4-pyridinones As Orally Bioavailable H3 Receptor Antagonists and Β-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer's Disease.

Design, Synthesis, and Biological Evaluation of Scutellarein Carbamate Derivatives As Potential Multifunctional Agents for the Treatment of Alzheimer's Disease

Structural Optimization and Biological Evaluation of Substituted Bisphenol A Derivatives As Beta-Amyloid Peptide Aggregation Inhibitors.

Design, synthesis and biological evaluation of 1-aryldonepezil analogues as anti-Alzheimer's disease agents

Synthesis and Biological Evaluation of Novel N,N '-Bis-methylenedioxybenzyl-alkylenediamines As Bivalent Anti-Alzheimer Disease Ligands

Development of Multifunctional Pyrimidinylthiourea Derivatives As Potential Anti-Alzheimer Agents.

Design, synthesis, and evaluation of 2-piperidone derivatives for the inhibition of β-amyloid aggregation and inflammation mediated neurotoxicity

Discovery of Novel Propargylamine-Modified 4-Aminoalkyl Imidazole Substituted Pyrimidinylthiourea Derivatives As Multifunctional Agents for the Treatment of Alzheimer's Disease.

Discovery of Compounds That Selectively Repress the Amyloidogenic Processing of the Amyloid Precursor Protein: Design, Synthesis and Pharmacological Evaluation of Diphenylpyrazoles

Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential anti-Alzheimer's Disease Agents.

Synthesis and Evaluation of Novel GSK-3β Inhibitors As Multifunctional Agents Against Alzheimer's Disease

Design, synthesis, and biological evaluation of tetrahydropyrimidine analogue as GSK-3β/Aβ aggregation inhibitor and anti-Alzheimer's agent

Design, synthesis and biological evaluation of novel pyrazolinone derivatives as multifunctional ligands for the treatment of Alzheimer's disease

Design, Synthesis and Biological Evaluation of 1-Phenyl-ethanone Derivatives for Multi-Targeted Treatment of Alzheimer's Disease

Synthesis and in Vitro Evaluation of Novel Indanone Derivatives Targeting Β-Amyloid

Discovery, Structure-Based Modification, in Vitro, in Vivo, and in Silico Exploration of M-Sulfamoyl Benzoamide Derivatives As Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer's Disease.

Design, synthesis, and activity evaluation of novel multitargeted l‐tryptophan derivatives with powerful antioxidant activity against Alzheimer's disease